ArticleRedox biology2026
8-oxo-7,8-dihydroguanosine (8-oxo-Guo) drives pulmonary inflammatory pathways through pattern recognition receptors.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
8-oxo-7,8-dihydroguanosine (8-oxo-Guo) is a key biomarker of oxidative stress and nucleic acid damage, the levels of which positively correlate with aging and age-related diseases. Notably, in inflammatory diseases, 8-oxo-Guo levels are significantly elevated. In vivo mouse experiments showed that a tail vein injection of 8-oxo-Guo increased inflammatory factor expression in peripheral blood and lung tissue and increased the proportion of M1-type macrophages in bronchoalveolar lavage fluid, indicating the induction of macrophage polarization and pulmonary inflammation. In vitro studies of mouse alveolar macrophages revealed that 8-oxo-Guo activates inflammatory pathways via Nucleotide-binding oligomerization domain-containing protein 2 (NOD2), Toll-like receptor 2 (TLR2), and NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) receptors synergistically with single-stranded RNA (e.g., polyuridylic acid or uracil-rich microRNA). NOD2 appears as a core regulatory target, in which its inhibition effectively reduces inflammation. The present study elucidates a novel mechanism whereby endogenous 8-oxo-Guo drives pulmonary inflammation through these receptors in alveolar macrophages, indicating that 8-oxo-Guo is a key inflammatory initiator in alveolar macrophages and mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.